Serology Characteristics of SARS-CoV-2 Infection After Exposure and Post-symptom Onset
Overview
Authors
Affiliations
Background: Timely diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a prerequisite for treatment and prevention. The serology characteristics and complement diagnosis value of the antibody test to RNA test need to be demonstrated.
Method: Serial sera of 80 patients with PCR-confirmed coronavirus disease 2019 (COVID-19) were collected at the First Affiliated Hospital of Zhejiang University, Hangzhou, China. Total antibody (Ab), IgM and IgG antibodies against SARS-CoV-2 were detected, and the antibody dynamics during the infection were described.
Results: The seroconversion rates for Ab, IgM and IgG were 98.8%, 93.8% and 93.8%, respectively. The first detectible serology marker was Ab, followed by IgM and IgG, with a median seroconversion time of 15, 18 and 20 days post exposure (d.p.e.) or 9, 10 and 12 days post onset (d.p.o.), respectively. The antibody levels increased rapidly beginning at 6 d.p.o. and were accompanied by a decline in viral load. For patients in the early stage of illness (0-7 d.p.o), Ab showed the highest sensitivity (64.1%) compared with IgM and IgG (33.3% for both; p<0.001). The sensitivities of Ab, IgM and IgG increased to 100%, 96.7% and 93.3%, respectively, 2 weeks later. When the same antibody type was detected, no significant difference was observed between enzyme-linked immunosorbent assays and other forms of immunoassays.
Conclusions: A typical acute antibody response is induced during SARS-CoV-2 infection. Serology testing provides an important complement to RNA testing in the later stages of illness for pathogenic-specific diagnosis and helpful information to evaluate the adapted immunity status of patients.
Dubinovic-Rekic A, Pranjic N Mater Sociomed. 2025; 36(3):222-228.
PMID: 39749151 PMC: 11693126. DOI: 10.5455/msm.2024.36.222-228.
Pniewska S, Drozd M, Mussida A, Brambilla D, Chiari M, Rastawicki W Sensors (Basel). 2024; 24(23).
PMID: 39686303 PMC: 11644834. DOI: 10.3390/s24237766.
Katoh S, Yasuda I, Kitakawa K, Hamaguchi S, Sando E Trop Med Health. 2024; 52(1):65.
PMID: 39343951 PMC: 11439312. DOI: 10.1186/s41182-024-00635-y.
Sartingen N, Sturmer V, Kaltenbock M, Muller T, Schnitzler P, Kreshuk A Viruses. 2024; 16(9).
PMID: 39339949 PMC: 11437451. DOI: 10.3390/v16091473.
Gu Z, Song R, Zhang Y, Hao Y, Sheng S, Chen X Heliyon. 2024; 10(15):e35425.
PMID: 39165927 PMC: 11334814. DOI: 10.1016/j.heliyon.2024.e35425.